NSE ScannerMedical Devices & Supplies · Medical Distributors · NSE: ENTERO · data 2026-11-01
Entero Healthcare Solutions Limited
In plain words
Price: 18.0% below its 52-week high of ₹1,920.
Delivery: 51.5% of traded shares were kept for delivery over the last 10 sessions, against 50.0% over the last 60.
Latest results: a net profit of ₹38 cr for the quarter ended Jun 2026 (+37.3% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹7,128 cr |
| Net profit (last 12 months) | ₹125 cr |
| Sales growth, 3 years (yearly) | 25.9% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 52.4% (unchanged in a year), pledged 0.0%, institutions 26.9%.
P/E 54.7, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 6.7%, ROCE 11.6%, operating margin 3.7%: how much profit it earns on the money it uses.
Debt/equity 0.40, Profit growth — and sales growth 25.9% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (6.7%).
- Thin operating margin (3.7%).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
ENTERO Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹1,940.49 crore, up 38.2% YoY and up 1.6% QoQ.
Net profit was ₹38.16 crore, up 37.3% YoY and up 36.2% QoQ.
Operating margin was 5% (3.6% a year ago).
EPS was ₹8.77, up 37.2% YoY and up 36.2% QoQ.
ENTERO के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹1,940.49 करोड़; पिछले साल की तुलना में 38.2% की बढ़त, पिछली तिमाही की तुलना में 1.6% की बढ़त।
शुद्ध मुनाफ़ा: ₹38.16 करोड़; पिछले साल की तुलना में 37.3% की बढ़त, पिछली तिमाही की तुलना में 36.2% की बढ़त।
ऑपरेटिंग मार्जिन: 5% (एक साल पहले 3.6%)।
EPS: ₹8.77; पिछले साल की तुलना में 37.2% की बढ़त, पिछली तिमाही की तुलना में 36.2% की बढ़त।
ENTEROના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹1,940.49 કરોડ; ગયા વર્ષની સરખામણીએ 38.2% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 1.6% વધારો.
ચોખ્ખો નફો: ₹38.16 કરોડ; ગયા વર્ષની સરખામણીએ 37.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 36.2% વધારો.
ઓપરેટિંગ માર્જિન: 5% (એક વર્ષ પહેલાં 3.6%).
EPS: ₹8.77; ગયા વર્ષની સરખામણીએ 37.2% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 36.2% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
15/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 52.9% over the last 20 sessions vs 39.9% in the 40 before (1.33x); shares delivered per day 0.37x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹69.41 cr in bulk/block deals over 90 days (0 net buying days, 1 net selling day): more sold than bought.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Results
- 18 Sept 26Deal Block deal: HDFC MUTUAL FUND bought ₹235.6 cr (net ₹0 cr) +7.7% next session
- 17 Sept 26Deal Bulk deal: PRASID UNO FAMILY TRUST sold ₹69.41 cr 0.0% next session
- 7 Aug 26Results Q1 FY27 results: profit +37.3% YoY +5.8% next session
- 25 May 26Results Q4 FY26 results: profit +9.0% YoY -5.2% next session
- 12 Feb 26Results Q3 FY26 results: profit +8.6% YoY 0.0% next session
- 12 Nov 25Results Q2 FY26 results: profit +33.8% YoY +5.3% next session
- 8 Aug 25Results Q1 FY26 results: profit +35.4% YoY -5.8% next session
- 27 May 25Results Q4 FY25 results: profit +22.5% YoY -9.2% next session
- 13 Feb 25Results Q3 FY25 results: profit +275.2% YoY -5.5% next session
- 13 Nov 24Results Q2 FY25 results: net profit ₹23.6 cr -4.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹1,940 cr | ₹38 cr | +37.3% | 5.0% | 8.77 |
| Mar 2026 | ₹1,910 cr | ₹28 cr | +9.0% | 4.5% | 6.44 |
| Dec 2025 | ₹1,707 cr | ₹28 cr | +8.6% | 4.0% | 6.35 |
| Sept 2025 | ₹1,571 cr | ₹32 cr | +33.8% | 4.0% | 7.26 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 52.40% | 52.40% | 52.42% | 52.42% |
| Foreign institutions (FII) | 5.77% | 4.37% | 4.03% | 5.14% |
| Domestic institutions (DII) | 21.16% | 15.48% | 16.62% | 16.42% |
| Mutual funds | 11.15% | 8.97% | 9.52% | 10.25% |
| Retail investors | 10.90% | 10.83% | 10.18% | 9.60% |
| Number of shareholders | 40,919 | 39,709 | 39,084 | 40,333 |
Common questions
What was Entero Healthcare Solutions Limited's latest quarterly profit?
Entero Healthcare Solutions Limited reported a net profit of ₹38 cr for the quarter ended Jun 2026 (+37.3% on the same quarter a year earlier), on revenue of ₹1,940 cr.
How much do promoters hold in Entero Healthcare Solutions Limited?
Promoters held 52.40% of Entero Healthcare Solutions Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Entero Healthcare Solutions Limited debt-free?
Its latest reported debt-to-equity ratio is 0.4.
What is Entero Healthcare Solutions Limited's P/E ratio?
About 54.7, based on the last 12 months' earnings and a price of ₹1,575.2 (data 2026-11-01).
What is the 52-week high and low of Entero Healthcare Solutions Limited?
The 52-week high is ₹1,920 and the 52-week low is ₹944.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Entero Healthcare Solutions Limited | ₹1,575.2 | ₹6,850 cr | 54.7 | — | 6.7% | 11.6% | 0.4 | +42.8% |
| QMS Medical Allied Services Limited | ₹181.17 | ₹350 cr | 31.6 | — | 10.5% | 18.9% | 0.71 | +66.3% |
| Vijaypd Ceutical Limited | ₹76.05 | ₹149 cr | 29.6 | 2.8 | 11.8% | 9.2% | 0.7 | +70.9% |
| Balaxi Pharmaceuticals Limited | ₹19.15 | ₹106 cr | — | — | 0.6% | — | 0.23 | -55.3% |
| Aakaar Medical Technologies Limited | ₹71 | ₹101 cr | 15.2 | 1.8 | 17.1% | 25.8% | 0.34 | -15.5% |
| Vivo Bio Tech Ltd. | ₹13.72 | ₹31 cr | — | — | -2% | 8.3% | 0.72 | -31.9% |
Compare ENTERO with QMSMEDI in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ENTERO in NSE Scanner →